Endocrine aspects of the diagnosis and treatment of male sexual dysfunction: new ISSM Guidelines
01 September 2011
Endocrine aspects of male sexual dysfunctions. Buvat J, Maggi M, Gooren L, et al. J Sex Med 2010;7(4 Pt 2):1627-1656.
This article is a summary of the report by the Endocrine Aspects of Male Sexual Dysfunctions international experts Committee aimed to provide guidelines based on best evidence for the diagnosis and treatment of endocrine-related male sexual dysfunction.1 It was prepared in collaboration with the Standards Committee of the International Society of Sexual Medicine (ISSM) and presented at the Third International Consultation of Sexual Medicine (ICSM) in Paris in July 2009. The report was finalized following detailed review of the medical literature, extensive discussion over two years, and public presentation and discussion with other experts, and provides a standardized process for the diagnosis and treatment of endocrine-related male sexual dysfunction. A total of 30 evidence-based recommendations were made and the supporting evidence detailed, including updated knowledge on the prostate and cardiovascular safety of testosterone; key recommendations are presented in this article.
What this study adds
These recommendations have been formulated by expert grading of the evidence base of the medical literature and interactive discussion. The Endocrine Aspects of Male Sexual Dysfunctions Committee comprised 11 experts from eight countries and four continents, in collaboration with the Endocrine subcommittee of the Standards’ Committee of the ISSM. Their findings confirm that men with ED, hypoactive sexual desire and retarded ejaculation, as well as those with visceral obesity and metabolic diseases, should be screened for TD and treated as necessary. Prospective interventional studies are required before recommending screening for TD in more conditions, including cardiovascular diseases.